{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:11:20Z","timestamp":1789132280008,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1111\/jth.15892","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T23:48:21Z","timestamp":1663890501000},"page":"2810-2822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long\u2010term follow\u2010up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post\u2010HERCULES study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-6517","authenticated-orcid":false,"given":"Marie","family":"Scully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-5197","authenticated-orcid":false,"given":"Katerina","family":"Pavenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-8639","authenticated-orcid":false,"given":"Ara","family":"Metjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7225","authenticated-orcid":false,"given":"Paul","family":"Kn\u00f6bl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6910","authenticated-orcid":false,"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-2095","authenticated-orcid":false,"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-7135","authenticated-orcid":false,"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-4882","authenticated-orcid":false,"given":"Jessica","family":"Minkue Mi Edou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-723X","authenticated-orcid":false,"given":"Rui","family":"De Passos Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-5338","authenticated-orcid":false,"given":"Filip","family":"Callewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-6913","authenticated-orcid":false,"given":"Sriya","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-6053","authenticated-orcid":false,"given":"Julie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15892_bb0010","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1111\/jth.15892_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17474086.2019.1611423","article-title":"An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura","volume":"12","author":"Joly","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1111\/jth.15892_bb0020","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long\u2010term follow\u2010up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1111\/jth.15892_bb0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1111\/jth.15892_bb0030","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1111\/jth.15892_bb0035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long\u2010term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"20","key":"10.1111\/jth.15892_bb0040","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15892_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long\u2010term deficits in health\u2010related quality of life after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"},{"issue":"7","key":"10.1111\/jth.15892_bb0050","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","article-title":"Long\u2010term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Riva","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1111\/jth.15892_bb0055","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1002\/ajh.24138","article-title":"Increased morbidity during long\u2010term follow\u2010up of survivors of thrombotic thrombocytopenic purpura","volume":"90","author":"Chaturvedi","year":"2015","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1111\/jth.15892_bb0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1111\/jth.15892_bb0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX\u20100081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1111\/jth.15892_bb0070","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti\u2010VWF Nanobody ALX\u20100681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1111\/jth.15892_bb0075","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15892_bb0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1111\/jth.15892_bb0085","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1111\/jth.15892_bb0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune\u2010mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1111\/jth.15892_bb0095","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real\u2010world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1111\/jth.15892_bb0100","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real\u2010world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1111\/jth.15892_bb0105","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1111\/jth.15892_bb0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J Clin Exp Neuropsychol"},{"issue":"8","key":"10.1111\/jth.15892_bb0115","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six\u2010item short\u2010form survey for measuring headache impact: the HIT\u20106","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1111\/jth.15892_bb0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102410379890","article-title":"Validation of the Headache Impact Test (HIT\u20106) across episodic and chronic migraine","volume":"31","author":"Yang","year":"2011","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1111\/jth.15892_bb0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36\u2010item short\u2010form health survey (SF\u201036). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1111\/jth.15892_bb0130","unstructured":"RAND corporation. 36\u2010item short form scoring instructions. Accessed January 26, 2022. https:\/\/www.rand.org\/health\u2010care\/surveys_tools\/mos\/36\u2010item\u2010short\u2010form\/scoring.html"},{"issue":"7","key":"10.1111\/jth.15892_bb0135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/13854046.2015.1107137","article-title":"The minimum clinically important difference in the Repeatable Battery for the Assessment of Neuropsychological Status","volume":"29","author":"Phillips","year":"2015","journal-title":"Clin N\u2011europsychol"},{"issue":"3","key":"10.1111\/jth.15892_bb0140","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ajh.25002","article-title":"No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry","volume":"93","author":"Masias","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1111\/jth.15892_bb0145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1111\/jth.15892_bb0150","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.15892_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long\u2010term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta\u2010analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1111\/jth.15892_bb0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1111\/jth.15892_bb0165","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long\u2010term relapses in immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1111\/jth.15892_bb0170","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.21833","article-title":"Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic\u2010uremic syndromes","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:36:01Z","timestamp":1761536161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622183790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1538783622183790"],"URL":"https:\/\/doi.org\/10.1111\/jth.15892","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long\u2010term follow\u2010up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post\u2010HERCULES study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 Sanofi and The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}